News

June 07, 2007
ImmunoGen, Inc. to Present at Needham & Company, LLC's Sixth Annual Biotechnology and Medical Technology Conference

CAMBRIDGE, Mass., Jun 07, 2007 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at Needham & Company, LLC's Sixth Annual Biotechnology and Medical Technology Conference will be webcast live. The presentation is scheduled to begin at 10:30 am ET on Thursday, June 14, 2007, and will be given at the New York Palace Hotel in New York. The presentation will provide an update on ImmunoGen.

The webcast can be accessed through the "Investor Relations" section of the ImmunoGen website, www.immunogen.com.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company's proprietary Tumor-Activated Prodrug (TAP) technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing - huN901-DM1 and huC242-DM4. Three anticancer compounds are in clinical testing through ImmunoGen's collaborations with other companies - AVE9633 and AVE1642, in development by sanofi-aventis, and trastuzumab-DM1, in development by Genentech. Multiple compounds are in research/preclinical development.

ImmunoGen, Inc.
Carol Hausner, 617-995-2500
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com

YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE

Notice

The "Yes" link below will take you out of the AbbVie family of websites.

Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie.

The Internet site that you have requested may not be optimized to your screen size.

Do you wish to leave this site?